IQIRVO 80 mg FILM-COATED TABLETS
Ask a doctor about a prescription for IQIRVO 80 mg FILM-COATED TABLETS
How to use IQIRVO 80 mg FILM-COATED TABLETS
Introduction
Package Leaflet: Information for the Patient
Iqirvo 80mg film-coated tablets
elafibranor
This medicinal product is subject to additional monitoring, which will allow for the quick identification of new safety information. You can help by reporting any side effects you may get. The last section of section 4 will tell you how to report side effects.
Read all of this leaflet carefully before you start taking this medicine, because it contains important information for you.
- Keep this leaflet, you may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.
Contents of the pack
- What is Iqirvo and what is it used for
- What you need to know before you take Iqirvo
- How to take Iqirvo
- Possible side effects
- Storage of Iqirvo
- Contents of the pack and other information
1. What is Iqirvo and what is it used for
Iqirvo contains the active substance elafibranor, which acts on two types of receptors (PPAR alpha and PPAR delta).
This medicine is used in adults to treat primary biliary cholangitis (PBC), a type of liver disease in which the bile ducts are slowly destroyed, making it difficult for bile to flow. Bile is a liquid that helps digest food, especially fats. When bile cannot flow into the digestive tract, it builds up in the liver (a condition called cholestasis), where it damages liver tissue. This can reduce liver function and cause inflammation. Iqirvo can be used alone or in combination with ursodeoxycholic acid (UDCA) in patients who cannot use UDCA.
The active substance in Iqirvo, elafibranor, works by activating PPAR alpha and PPAR delta receptors. These proteins are thought to regulate bile acid levels, inflammation, and fibrosis (scarring). This reduces the production and accumulation of bile in the liver and also reduces liver inflammation.
2. What you need to know before you take Iqirvo
Do not take Iqirvo
- if you are allergic to elafibranor or any of the other ingredients of this medicine (listed in section 6).
- if you are pregnant, think you may be pregnant or are not using any contraceptive method to prevent pregnancy.
Warnings and precautions
Iqirvo may increase blood levels of liver enzymes and bilirubin (a breakdown product of red blood cells). Your doctor will perform blood tests to check your liver before and during treatment. If the results of these liver tests are abnormal, your doctor may temporarily stop treatment until they return to normal. Tell your doctor immediately if you experience symptoms of liver dysfunction, such as yellowing of the skin and eyes (jaundice), abdominal pain, nausea, vomiting, fatigue, loss of appetite, and dark urine.
Iqirvo may increase blood levels of creatine phosphokinase (an enzyme released into the blood when muscle is damaged). Your doctor will perform blood tests to check your creatine phosphokinase levels before and during treatment, especially if you are taking medicines known as HMG-CoA reductase inhibitors, such as atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin. Tell your doctor immediately if you experience unexplained muscle pain, inflammation, or weakness while taking this medicine.
Children and adolescents
This medicine must not be used in children and adolescents under 18 years of age.
Other medicines and Iqirvo
Tell your doctor if you are taking, have recently taken or might take any other medicines.
Pregnancy
Do not take Iqirvo if you are pregnant, think you may be pregnant or are not using any contraceptive method to prevent pregnancy. Iqirvo may harm the fetus.
Your doctor may perform a pregnancy test before starting treatment with Iqirvo to ensure you are not pregnant before starting it.
If you are a woman of childbearing potential, you must use an effective contraceptive method (birth control) while taking this medicine and for at least 3 weeks after stopping treatment to prevent harm to the fetus. Your doctor will advise you on the best contraceptive method for you.
Breast-feeding
It is not known if Iqirvo passes into breast milk. The risk to the breast-fed child cannot be excluded.
Do not breast-feed your baby during treatment and for 3 weeks after the last dose.
Iqirvo contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet, which is essentially 'sodium-free'.
3. How to take Iqirvo
Take this medicine exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist.
The recommended dose is one 80 mg tablet once a day. Swallow the tablets whole with water.
Ask your doctor before taking Iqirvo if you have advanced cirrhosis (a type of chronic and progressive liver disease in which liver cells are replaced by scar tissue) with severely reduced liver function (Child-Pugh C).
If you take more Iqirvo than you should
If you take more medicine than you should, talk to your doctor or go to the hospital immediately, taking the medicine pack and this leaflet with you.
If you forget to take Iqirvo
If you forget to take a dose of Iqirvo, skip the missed dose and take the next dose when it is due.
Do not take a double dose to make up for a forgotten dose.
If you stop taking Iqirvo
Do not stop taking this medicine without talking to your doctor first.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The possible side effects are:
Very common side effects (may affect more than 1 in 10 people):
- Abdominal pain
- Diarrhea
- Nausea
- Vomiting
Common side effects (may affect up to 1 in 10 people):
- Headache
- Constipation
- Gallstones (cholelithiasis) that can block the flow of bile, causing abdominal pain, nausea, or vomiting
- An increase in creatine phosphokinase, measured in blood tests
- Muscle pain (myalgia)
Uncommon side effects (may affect up to 1 in 100 people):
- Itchy skin rash (pruriginous rash)
- An increase in creatinine, measured in blood tests. Creatinine levels in the blood are measured to monitor kidney function.
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V*. By reporting side effects, you can help provide more information on the safety of this medicine.
5. Storage of Iqirvo
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of the month shown.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
6. Contents of the pack and other information
What Iqirvo contains
- The active substance is elafibranor.
- Each film-coated tablet contains 80 mg of elafibranor.
The other ingredients are:
- Tablet core:microcrystalline cellulose, povidone, sodium croscarmellose (see section 2 'Iqirvo contains sodium'), colloidal anhydrous silica, magnesium stearate.
- Film coating:partially hydrolyzed polyvinyl alcohol, titanium dioxide (E171), macrogol, talc, yellow iron oxide (E172), red iron oxide (E172).
Appearance and packaging
Iqirvo 80 mg are film-coated tablets, round and orange in color, approximately 8 mm in diameter, and identified with 'ELA 80' on one side.
Iqirvo is available in packs of 30 film-coated tablets, with a child-resistant closure.
Marketing Authorisation Holder
Ipsen Pharma
70 rue Balard
75015 Paris
France
Manufacturer
Delpharm Milano Srl
Via Salvatore Carnevale 1
Segrate, 20054
Italy
You can request more information about this medicine from the local representative of the Marketing Authorisation Holder:
België/Belgique/Belgien, Luxembourg/Luxemburg Ipsen NV België/Belgique/Belgien Tél/Tel: + 32 9 243 96 00 | Latvija Ipsen Pharma representative office Tel: +371 67622233 |
Ceská republika Ipsen Pharma, s.r.o. Tel: + 420 242 481 821 | Lietuva Ipsen Pharma SAS Lietuvos filialas Tel. +370 700 33305 |
Danmark, Norge, Suomi/Finland, Sverige, Ísland Institut Produits Synthèse (IPSEN) AB Sverige/Ruotsi/Svíþjóð Tlf/Puh/Tel/Sími: +46 8 451 60 00 | Magyarország IPSEN Pharma Hungary Kft. Tel.: +36 1 555 5930 |
Deutschland, Österreich Ipsen Pharma GmbH Deutschland Tel.: +49 89 2620 432 89 | Nederland Ipsen Farmaceutica B.V. Tel: + 31 (0) 23 554 1600 |
Ελλάδα, Κύπρος, Malta Ipsen Μονοπρόσωπη EΠΕ Ελλάδα Τηλ: + 30 210 984 3324 | Polska Ipsen Poland Sp. z o.o. Tel.: + 48 (0) 22 653 68 00 |
España Ipsen Pharma, S.A.U. Tel: + 34 936 858 100 | Portugal Ipsen Portugal - Produtos Farmacêuticos S.A. Tel: + 351 21 412 3550 |
France, Eesti, Hrvatska, Slovenija Ipsen Pharma France Tél: + 33 1 58 33 50 00 | România Ipsen Pharma România SRL Tel: + 40 21 231 27 20 |
Ireland Ipsen Pharmaceuticals Ltd. Tel: +353 1 809 8256 | Slovenská republika Ipsen Pharma, organizačná zložka Tel: + 420 242 481 821 |
Italia Ipsen SpA Tel: + 39 02 39 22 41 |
Date of last revision of this leaflet
This medicine has been authorized with a 'conditional approval'. This type of approval means that more information on this medicine is expected.
The European Medicines Agency will review the new information on this medicine at least once a year and this leaflet will be updated as necessary.
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu. There are also links to other websites on rare diseases and orphan medicines.
- Country of registration
- Active substance
- Prescription requiredYes
- Manufacturer
- This information is for reference only and does not constitute medical advice. Always consult a licensed doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
- Alternatives to IQIRVO 80 mg FILM-COATED TABLETSDosage form: CAPSULE, 1200 µgActive substance: odevixibatManufacturer: Ipsen PharmaPrescription requiredDosage form: CAPSULE, 200 µgActive substance: odevixibatManufacturer: Ipsen PharmaPrescription requiredDosage form: CAPSULE, 200 - REVIEW µgActive substance: odevixibatManufacturer: Ipsen PharmaPrescription required
Alternatives to IQIRVO 80 mg FILM-COATED TABLETS in other countries
The best alternatives with the same active ingredient and therapeutic effect.
Alternative to IQIRVO 80 mg FILM-COATED TABLETS in Ukraine
Online doctors for IQIRVO 80 mg FILM-COATED TABLETS
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for IQIRVO 80 mg FILM-COATED TABLETS – subject to medical assessment and local rules.
Get updates and exclusive offers
Be the first to know about new services, marketplace updates, and subscriber-only promos.
